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Abstract: Rotavirus is a primary cause of severe dehydrating gastroenteritis in infants and 
young children. The virus is sensitive to the antiviral effects triggered by the interferon 
(IFN)-signaling pathway, an important component of the host cell innate immune response. 
To counteract these effects, rotavirus encodes a nonstructural protein (NSP1) that induces 
the degradation of proteins involved in regulating IFN expression, such as members of the 
IFN regulatory factor (IRF) family. In some instances, NSP1 also subverts IFN expression 
by causing the degradation of a component of the E3 ubiquitin ligase complex responsible 
for activating NF-B. By antagonizing multiple components of the IFN-induction pathway, 
NSP1 aids viral spread and contributes to rotavirus pathogenesis. 
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1. Introduction  
The innate immune system provides an immediate mechanism of suppressing the replication and 
spread of viruses. The production of type I interferon (IFN), including IFN- and IFN- subtypes, is 
critical to an effective innate immune response. Type I IFNs activate the expression of hundreds of 
IFN-stimulated genes (ISGs), which play critical roles not only in the innate immune response, but also 
in B-cell and T-cell activation, cell cycle regulation, and apoptosis [1,2]. ISGs can interfere with 
viruses at various stages of their replicative cycle. To counteract the innate immune response, most 
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viruses have evolved mechanisms to subvert IFN signaling, including rotaviruses (RVs), members of 
the  Reoviridae family. RV antagonizes the IFN induction pathway through the action of the 
nonstructural protein NSP1, which induces the proteasomal degradation of one or more transcription 
factors necessary for the efficient expression of type I IFN (Figure 1).  
IFN Response to Viral Infection 
The IFN response can be triggered in virus-infected cells by the interaction of viral nucleic acids or 
proteins with pattern-recognition receptors (PRRs). Two families of PRRs have been identified as 
primary sensors of viral infection: the transmembrane TLRs (Toll-like receptors) and the cytoplasmic 
pathogen detectors, including the RNA sensors RIG-I (retinoic acid-inducible gene I) and MDA5 
(melanoma differentiation-associated gene 5), and the DNA sensor DAI (DNA-dependent activator of 
IFN-regulatory factors) [3-5]. The interaction of viral nucleic acids with PRRs leads to the activation 
of IFN regulatory factors (IRFs) and nuclear factor (NF)-B, which translocate from the cytoplasm to 
the nucleus where they stimulate transcription of type I IFN genes. Collectively, IFN expression 
requires the participation of several transcription factors, providing viruses many potential targets for 
antagonizing the IFN signaling pathway [6].  
Members of the IRF family of proteins include IRF3 and IRF7, key regulators of type I IFN 
expression [7]. IRF3 is constitutively expressed in cells where it accumulates at elevated levels in the 
cytoplasm. In contrast, IRF7 is present in most cells at very low levels, and its expression is amplified 
by type I IFN [7,8]. Both IRF3 and IRF7 reside in an inactive state in the cytoplasm and are activated 
by phosphorylation of residues in the C-terminal regulatory region by the kinases TBK1 or   
IKK- [9,10]. Phosphorylated IRF3 and IRF7 form homodimers or heterodimers, which then 
translocate to the nucleus. IRF3 homodimers, IRF7 homodimers, and IRF3/IRF7 heterodimers have 
differential effects on the expression of type I IFN gene-family members [11-13]. IRF3, in cooperation 
with other transcription factors, is an activator of IFN- and a few IFN- subtypes. IRF7 has broader 
effects than IRF3, promoting the expression of even higher levels of IFN- and a greater number of 
IFN- subtypes. Maximal expression of type I IFN is achieved through the combined actions of IRF3 
and IRF7 [9,12,14,15]. Other members of the IRF family, such as IRF5, are known to play important 
roles in the development of antiviral responses. However, their contribution to effective IFN 
expression is not well understood and may vary depending on host species [4]. 
Secreted type I IFNs bind to type I IFN receptors (IFNAR) and induce the formation of   
IFN-stimulated gene factor 3 (ISGF3), a heterotrimeric complex consisting of signal transducer and 
activator of transcription (STAT) 1, STAT2, and IRF9. ISGF3 translocates to the nucleus and 
stimulates transcription of ISGs, including IRF7. Thus, in most cell types, IRF7 levels are increased 
through positive feedback by type I IFNs [13,14]. However, IRF7 is constitutively expressed at high 
levels in plasmacytoid dendritic cells (pDC), the primary source of type I IFN in response to   
infection [16]. IRF7 has been shown to be crucial for virus-induced IFN- and IFN- expression in 
both pDC and non-pDC cell lines [17].  
NF-B is also required for inducing transcription of the IFN- gene, but not for   
IFN- genes [11,18]. NF-B subunits are held inactive in the cytoplasm through an interaction with 
inhibitors of B (IB). Phosporylation of IB by IB kinases (IKK/) results in its ubiquitination by Viruses 2009, 1                                       
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the E3 ligase Skp1/Cul1/F-box complex SCF
-TrCP, and subsequent degradation by the   
proteasome [19]. IB degradation releases the NF-B heterodimer p50/p65, which allows it to 
translocate to the nucleus for promoter binding and transcription of genes containing NF-B response 
elements. 
Figure 1. Summary of NSP1 inhibition of the innate immune response pathway. 
Activation of dsRNA sensors in the cytoplasm (such as RIG-I) or bound to membranes 
(such as TLR3) stimulates pathways that result in the phosphorylation of IRF3 and IRF7 
by IKK- and TBK1. Phosphorylation allows for the formation of IRF3 homodimers, IRF7 
homodimers, or IRF3/IRF7 heterodimers. RIG-I activation also results in the ubiquitination 
(Ub) of IB by the E3 ligase Skp1/Cul1/F-box complex SCF
-TrCP and subsequent 
degradation by the proteasome. Degradation of IB frees the NF-B complex (p50 and 
p65), which moves to the nucleus. The binding of NF-B and IRF dimers to the IFN- 
promoter results in transcription and secretion of IFN-, which binds to type I IFN 
receptors (IFNAR). IFNAR signals the ISGF3 complex, consisting of STAT1, STAT2, and 
IRF9, to produce additional IRF7 and type I IFNs, thus amplifying the IFN response. The 
NSP1 protein from different RVs has a range of activities. Some RV NSP1 proteins inhibit 
the type I IFN response by degrading IRF3 and IRF7, while at least one NSP1 prevents 
type I IFN induction by degrading -TrCP and preventing the nuclear translocation of  
NF-B. 
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2. Rotavirus Biology 
RV is one of several genera of segmented double-stranded (ds) RNA viruses within the family 
Reoviridae. RV is a primary cause of severe dehydrating gastroenteritis in children under 5 years of 
age, causing approximately 500,000 deaths worldwide each year [20]. Though the global burden of 
diarrheal disease has been decreasing, children living in developing countries are more likely to die 
from RV infection [21]. The introduction of vaccines in some countries in North and Latin America, 
Europe, and Australia has reduced the number of cases of severe diarrhea and deaths. These vaccines 
are currently not available or not affordable in the poorest countries, and their efficacy may be 
suboptimal in impoverished settings. This latter issue may stimulate renewed efforts to modify existing 
or to develop a new generation of more efficacious vaccines. One potential strategy for developing 
new vaccine candidates is to engineer human RVs with a weakened ability to antagonize host IFN 
induction pathways.  
2.1. Replication 
The RV virion is an icosahedral particle composed of three concentric layers of protein that 
encapsidate 11 segments of dsRNA (Figure 2) [22,23]. The virion core includes the inner shell protein 
VP2, small amounts of the viral RNA-dependent RNA polymerase (RdRP) VP1 and the   
mRNA-capping enzyme VP3, and the segmented dsRNA genome [24-26]. Cores surrounded by a 
protein layer formed by VP6 represent double-layered particles (DLPs). In the infected cell, DLPs are 
transcriptionally active and are responsible for the synthesis of the 11 viral mRNAs [27,28]. The outer 
protein layer of the capsid is comprised predominantly of the glycoprotein VP7. Protruding from the 
VP7 layer are spikes formed by the protease-sensitive attachment protein VP4. VP4 and VP7 induce 
neutralizing antibody responses in the infected host, and are the basis for immunological protection 
against subsequent disease [29]. 
RV mRNAs contain methylated 5' caps but lack 3' poly(A) tails [31,32]. Translation of viral 
mRNAs yields six structural proteins (VP1-VP4, VP6-VP7) and six nonstructural proteins   
(NSP1-NSP6). In addition to serving as templates for protein synthesis, RV mRNAs are also used by 
the viral RdRP as templates for the synthesis of genomic dsRNAs [33,34]. Genome replication and 
packaging occur in coordination with the assembly of cores, which takes place in cytoplasmic 
inclusion bodies known as viroplasms [26,35]. DLPs are also assembled in association with 
viroplasms, and then migrate to the endoplasmic reticulum (ER), where via budding the particles 
acquire the outer capsid VP7-VP4 protein shell [36]. The predominant mechanism of virus release 
from RV-infected cells is by lysis, though there is evidence that a subpopulation of virions may be 
released from the apical membrane of polarized cells by a non-lytic mechanism [37,38].  
The segmented character of the RV dsRNA genome allows distinct strains of the virus to exchange 
(reassort) genetic material during coinfection [39]. Such reassortment provides a mechanism for the 
rapid evolution of the virus and possibly the emergence of new antigenically-distinct virus strains. 
Selective pressures placed on individual viruses in nature may result in the maintenance of certain 
genome constellations encoding viral proteins that function optimally as a set, limiting the extent of 
reassortment.  Viruses 2009, 1                                       
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Figure 2. Three-dimensional structure of the RV virion. Genomic dsRNAs are associated 
with the RdRP VP1 and the capping enzyme VP3 on the interior side of the VP2 (green) 
core shell. An intermediate layer of VP6 (blue) surrounds the core. The outer layer of the 
virion is comprised of a VP7 capsid (yellow) with VP4 spikes (orange) protruding through 
this shell, completing the infectious virion. Figure was kindly provided by B.V.V. Prasad 
(Baylor College of Medicine) and details are given in [22,25,30].  
 
 
2.2. Classification 
RVs are classified into seven distinct groups, A to G, based on the antigenicity of the VP6 protein. 
Those in group A represent the major causative agents of acute gastroenteritis in humans and animals. 
Human group A RVs are divided into three distinct genogroups based on overall similarity to the three 
prototype strains: Wa, DS-1, and AU-1 [40]. Animal group A RVs are similarly divided into 
genogroups, though the divisions are more complex, with some genogroups including strains of RVs 
isolated from different animal species [41,42]. The antigenic and sequence characteristics of the outer 
capsid proteins VP7 (glycoprotein) and VP4 (protease-sensitive) have been used to classify group A 
RVs into G and P serotypes and genotypes [43]. Thus far, 22 G genotypes and 31 P genotypes have 
been defined [41,44-47]. Recently, a comprehensive sequence-based classification and nomenclature 
system was defined for RV, allowing each genome segment to be assigned a particular genotype [41].  
2.3. Pathogenesis 
RV infects mature differentiated enterocytes near the tips of the villi of the small intestine, causing 
mild inflammation, severe villus blunting, and malabsorption in the small intestine [48,49]. These 
effects contribute to the severe watery diarrhea and vomiting that are characteristic of RV disease, 
which in their most extreme manifestations can lead to death due to dehydration. Recent studies Viruses 2009, 1                                       
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indicate that RV infections in children and animal model systems are not always limited to the 
intestine, but in some cases can spread beyond the gut, causing a transient viremia and a more systemic 
infection that involves the liver, lung, kidney, spleen, and mesenteric lymph nodes [49-54].  
2.4. RV Host Range Restriction  
RVs are highly infectious in their natural (homologous) hosts, with even small amounts of virus  
(<1 plaque-forming units) capable of causing productive infection and severe disease. In contrast, 
successful RV infection of a heterologous host typically requires a concentrated-virus inoculum, yields 
little progeny virus, and is asymptomatic. The characteristic attenuated phenotype of RVs in their 
heterologous hosts has provided the foundation for the creation of human vaccines from bovine 
(RotaTeq, Merck) and rhesus (RotaShield, Wyeth) strains of RVs [21].  
The basis for RV host range restriction is not fully understood, but analysis of the growth and 
virulence characteristics of RV reassortants has identified several gene products that may be involved. 
The outer capsid proteins VP4 and VP7 have been implicated in species-specific RV growth due to 
their roles in virus attachment and entry [55-57]. Moreover, studies of reassortants indicate that the RV 
enterotoxin protein NSP4, host translation inhibitor protein NSP3, and RNA capping enzyme VP3 
influence the growth, spread, and virulence of viruses in different animal species [36,53,54,57]. A 
study investigating viral genes of murine RVs responsible for virulence in a mouse model obtained 
strong evidence that NSP1 has a role in viral pathogenesis [55]. Notably, the VP3, VP4, VP7, NSP1 
and NSP4 proteins each show a degree of species-specific sequence variation, consistent with the idea 
that the activities of these proteins may vary depending on host cell type and thus provide a partial 
basis for host cell restriction. 
2.5. Role of IFN in RV infection 
Rotavirus infection stimulates the production of type I and II IFN in children and animals [58-60]. 
Elevated IFN- is present both in the serum and stool of the infected host [59,61,62]. IFN- 
administered prior to infection reduces RV-associated diarrhea in bovine and porcine models of 
infection, indicating that IFN restricts RV growth in some animals [63,64]. In contrast, IFN 
pretreatment of neonatal mice has little or no effect on the course of diarrhea or virus shedding caused 
by infection with some strains of RV [65]. More recent studies have shown that homologous and 
heterologous strains of RV differ in the ability to spread in mice deficient in IFN signaling. These 
results raise the possibility that the host IFN response, and the capacity of the virus to overcome it, 
may play a role in limiting intestinal replication and extraintestinal spread [66].  
Type I IFNs also inhibit the growth of RVs in cell culture, although RV is not as sensitive to IFN as 
vesicular stomatitis virus (VSV) [67,68]. The human intestinal epithelial cell lines HT29 and Caco-2 
cells are resistant to RV infection when pretreated with IFN- [69]. HT29 cells do not express IFN- 
mRNA following RV infection with the simian strain RRV, though evidence of NF-B and NF-B-
dependent chemokine expression is apparent [70-72].  
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2.6. Properties of NSP1 
NSP1 (referred to as NS53 or VP5 in early literature) is the ~58-kDa protein product of RV genome 
segment 5 (Figure 3A). The protein accumulates at low levels in the cytoplasm of infected cells, 
possibly in association with the cytoskeleton [73-75]. The gene 5 RNA of group A RVs is unique in 
that its total length, as well as that of its open reading frame (ORF), can vary considerably among 
different virus strains. As a result, the NSP1 protein ranges in size from 486 to 496 amino acids for 
mammalian RV isolates, to as much as 577 amino acids for avian isolates. The amino acid sequence of 
NSP1 also differs significantly from strain to strain, more so than for any other RV protein. Notably, 
NSP1 sequence identities for mammalian RVs fall below 40%, and below 10% when the NSP1 
sequences of mammalian and avian strains are compared.  
Although divergent in primary sequence, the conservation of proline residues among NSP1 proteins 
suggests that they share similar higher order structures [76-78]. The N-terminal sequence of NSP1 is 
more conserved than that of the C terminus, and the N terminus includes the cysteine-rich motif,  
C-X2-C-X8-C-X2-C-X3-H-X-C-X2-C-X5-C (where X is any amino acid), which is common to all RV 
group A and C NSP1 proteins [75]. Early studies described the cysteine-histidine pattern as two zinc 
fingers, although recent studies have suggested this region is organized in a manner characteristic of 
those found in RING finger proteins (Figure 3B) [79,80]. NSP1 binds to zinc, but it has not been 
definitively demonstrated that the putative RING domain mediates this activity [81]. NSP1 also binds 
viral single-stranded (ss) RNA, and the RING domain is essential for this activity [74,81,82]. Mapping 
studies suggest that NSP1 recognizes the 5'-end of viral mRNAs, although the specific target of the 
binding activity has not been identified [74]. The role of the RNA-binding activity of NSP1 remains 
undefined. 
Two lines of evidence indicate that NSP1 is not essential for RV replication. First, reducing NSP1 
expression with gene-specific small-interfering RNAs during infection does not inhibit viral protein 
expression, gene synthesis, or virion assembly [35]. Secondly, RV variants have been isolated that 
encode C-truncated forms of NSP1, yet these viruses continue to replicate efficiently [82-85]. The 
most extreme example of an NSP1-defective variant is the bovine isolate A5-16, which encodes a 
truncated NSP1 that contains only the first 40 amino acids of the wild-type protein and therefore lacks 
the conserved zinc finger region [83,85]. This and other RV variants with a C-truncated NSP1 grow to 
titers similar to their wild-type parents in highly permissive MA104 cells [82,84]. However, in cells 
that are generally less permissive for RV replication (such as Caco-2 and FRhL2), wild-type RVs grow 
to titers that are at least one-log greater than NSP1-defective RVs, suggesting a role for NSP1 in 
enhancing cell-type specific viral replication [86].  
Rotaviruses encoding wild-type NSP1 form plaques that are considerably larger than those of RVs 
encoding C-truncated NSP1, suggesting that NSP1 is linked to the efficient cell-to-cell spread of the 
virus [83-85,87]. For example, SA11-5S, a simian RV variant that expresses a C-truncated NSP1 that 
lacks the last 17 amino acids of the full-length protein, produces plaques that are roughly half the size 
of those produced by its parental virus SA11-4F [84]. The small plaque size of NSP1-defective RVs is 
consistent with a role for NSP1 in subverting IFN-dependent pathways that would otherwise impede 
the successful movement of RV from infected to uninfected cells.  Viruses 2009, 1                                       
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Figure 3. (a) Schematic of general location of structural and functional domains in SA11-
4F NSP1; RING finger domain (RING); RNA-binding domain (RNA-BD); cytoplasmic 
localization domain (Cyto-LD); IRF-binding domain (IRF-BD). (b) Comparison of the 
consensus sequence of the RING finger domain of group A and C RV NSP1 and the viral 
RING domain. Conserved residues proposed to bind to first zinc ion highlighted in red 
boxes and conserved residues proposed to bind to second zinc ion highlighted in blue 
boxes. Numbers above boxes correspond to sequential numbering of metal ligands. 
Conserved tryptophan residues highlighted in violet circles. (c)  Predicted cross-brace 
organization of the RING finger domain of NSP1 and comparison to the known viral 
RING domain organization. Subscript numbers correspond to sequential numbering of 
metal ligands, and interspersed numbers correspond to the residues between metal ligands.  
 
3. Interaction of NSP1 with Transcription Factors of the IFN Induction Pathway 
3.1. NSP1-Induced Degradation of IRF Proteins 
The first evidence of an interplay between NSP1 and the innate immune system came from a yeast 
two-hybrid assay designed to identify proteins in a cDNA expression library of simian MA104 cells 
that interacted with NSP1 [88]. The analysis revealed that NSP1 of diverse origins (bovine B641 and Viruses 2009, 1                                       
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murine EW RVs) bound to IRF3. The association of NSP1 and IRF3 during RV infection was 
confirmed by co-immunoprecipitation assays performed with human Caco-2 cells infected with a 
simian RV (SA11-4F) [89]. Derivative experiments revealed that the C-terminal one-third of NSP1 
was sufficient for IRF3 interaction and that the deletion of a small C-terminal portion from NSP1 
prevented IRF3 binding [88,89].  
Infection of Caco-2 cells with SA11-4F reduced IRF3 to levels that were nearly undetectable. In 
contrast, infection with SA11-5S, which expresses a C-truncated NSP1, led to little decrease in IRF3 
levels [89]. This result correlated expression of intact NSP1 with the capacity of RV to induce the 
degradation of IRF3. Direct evidence for NSP1-mediated degradation of IRF3 was provided by 
transient expression assays in which wild-type NSP1 or C-truncated NSP1 was co-expressed along 
with IRF3. Wild-type NSP1, but not the C-truncated form, induced IRF3 degradation [86]. Treatment 
with the proteasome inhibitor MG132 prevented NSP1-mediated degradation of IRF3, suggesting that 
IRF3 turnover is dependent on proteasome activity [89,90]. The ability of NSP1 to induce IRF3 
degradation has been confirmed with multiple strains of RV in a variety of cell types   
(Table 1) [86,89-91].  
Ultimately, NSP1-induced degradation of IRF3 precludes activation and nuclear accumulation of 
this transcription factor, which has a primary role in IFN- expression. The importance that NSP1 has 
on IFN- expression has been assessed using a bioassay with a green fluorescent protein   
(GFP)- expressing recombinant VSV (VSV-GFP). VSV growth, as measured by GFP fluorescence, is 
strongly inhibited by the presence of IFN in cell culture media. Studies using the bioassay system 
showed that VSV-GFP grows well in media taken from cells infected with wild-type RVs (SA11-4F, 
30-19, and UK strains), demonstrating that RVs can suppress IFN expression [86]. In contrast, media 
recovered from cells infected with RV encoding a C-truncated NSP1 inhibited VSV-GFP growth, 
consistent with failure of its NSP1 to degrade IRF3. Importantly, the addition of a neutralizing anti-
IFN- antibody to the media recovered from cells infected with the NSP1-defective RV restored VSV-
GFP growth. These studies are supported by experiments measuring levels of secreted IFN-in RV-
infected cells, and provide evidence that intact NSP1 is a significant antagonist of IFN-  
expression [86,91].  
The importance of the putative RING domain of NSP1 on IRF3 degradation has been addressed by 
mutagenesis. Specifically, the mutation of conserved cysteine and histidine residues in the RING 
weakened interactions between NSP1 and IRF3 in yeast two hybrid assays and prevented NSP1 from 
inducing IRF3 degradation in co-expression assays [90]. These findings raise the possibility that the 
RING domain is essential for the activity of NSP1, much like the RING domains of some classes of E3 
ubiquitin ligases. However, it is possible that mutation of the RING domain caused such severe 
misfolding of NSP1 that a functionally-independent distant region of the protein involved in IRF3 
degradation was rendered inactive.  
Members of the IRF family share multiple structural features: all have an N-terminal DNA-binding 
domain that recognizes a consensus promoter sequence, several have a C-terminal serine-rich 
activation domain that is subject to phosphorylation, and others have a protein interaction domain that 
directs IRF dimerization [11]. These shared features raise the possibility that by interacting with one of 
the common domains, NSP1 can degrade members of the IRF family in addition to IRF3.  Viruses 2009, 1                                       
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Table 1. Capacity of NSP1 from RV strains shown to degrade endogenous IRF3. 
RV Strain  Host Species   IRF3 Degradation (Cell Type Tested)  Reference 
SA11-4F Simian   (Caco-2, FRhL2, MA104)  [86,89,90] 
30-19 Simian   (FRhL2) [89] 
RRV Simian   (Cos7, MEF)  [91,92] 
UK Bovine   (Cos7)                          
 (MEF) 
[91,92] 
B641 Bovine   [90]
NCDV Bovine                  
 (MEF)
[90,92]
OSU Porcine   (MA104, HEK293)  [90,92]
ETD Murine   (Cos7, MEF) [91,92]
EW Murine   (MEF)  [91] 
 
Indeed, transient expression assays have confirmed that the NSP1 product of the SA11-4F strain not 
only degrades IRF3, but also IRF5 and IRF7 through a proteasome-dependent process [86]. Thus, 
NSP1 represents a broad-spectrum antagonist of the IFN induction pathway. The biological 
significance of such broad activity is not clear, but the ability of NSP1 to induce the degradation of 
IRF7 suggests that some RVs may be particularly well suited to infect specialized cells, such as pDCs, 
that constitutively express IRF7. RVs can replicate in a minor proportion of pDCs, providing a means 
by which RVs can possibly escape the gut and give rise to a systemic infection [93]. Importantly, since 
pDCs are a primary source of IFN- in the infected host, the capacity of RVs to infect these cells and 
degrade their IRF7 component may represent a particularly effective mechanism of down-regulating 
IFN- expression in and around the gut. IRF5 is primarily detected in certain specialized cell types 
(e.g., B cells and DCs) [94]. The ability of NSP1 to degrade this transcription factor provides Viruses 2009, 1                                       
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additional evidence that NSP1 assists the virus in infecting specialized cells that allow trafficking 
beyond the gut. 
3.2. NSP1 Inhibition of the NF-B Pathway 
 
Numerous RV strains encoding full-length NSP1 have been shown to degrade IRF3   
(Table 1) [86,89-92,95]. Surprisingly, the porcine RV strain OSU was shown to inhibit the expression 
of IFN-, but failed to cause IRF3 degradation. In fact, IRF3 was activated and accumulated in the 
nucleus of OSU-infected cells. Further analysis has shown that OSU NSP1 can bind to IRF3, but less 
efficiently than B641 NSP1, suggesting a weak or unstable interaction incapable of triggering IRF3 
degradation [90,96]. Because IFN- expression requires not only activated IRF3, but also activated 
NF-B, Graff et al. [96] examined the fate of NF-B in OSU-infected cells. In uninfected cells,   
NF-B is retained in the cytoplasm due to its interaction with IB-. Activation of NF-B requires the 
interaction of phosphorylated IB- with the substrate recognition protein -transducin repeat 
containing protein (-TrCP) of the cellular E3 ubiquitin ligase complex SCF
-TrCP. This interaction 
results in the degradation of IB-, which then allows nuclear translocation of NF-B [19]. OSU 
NSP1 was shown to induce the degradation of -TrCP, which in turn prevents the degradation of  
IB-. As a result, IFN- gene expression is not upregulated in OSU-infected cells due to the absence 
of activated NF-B in the nucleus. The study by Graff et al. [96] also suggests that some NSP1 
proteins may have multiple specificities, resulting in the degradation of both IRF3 and -TrCP. The 
targeted degradation of a cellular F-box protein required for E3 ligase substrate recognition is a novel 
IFN evasion strategy not described previously for any other virus [96].  
Additional studies have indicated that some strains of RV (human Wa) stimulate the 
phosphorylation of NF-B. However, TNF--induced nuclear translocation and NF-B-driven gene 
expression are inhibited during infection. Similarly, some strains (Wa) activate STAT1 by inducing 
phosphorylation, but IFN--induced STAT1 and STAT2 nuclear translocation are inhibited by RV 
infection. The mechanism by which RV brings about these phenomena remains unresolved, but this 
activity is not due to the expression of NSP1 alone [97]. 
3.3. Host Cell Dependence of NSP1 Activity 
The neonatal mouse has been used extensively as an animal model system for identifying viral and 
host factors that influence RV growth, spread, and pathogenesis. Neonatal mice infected with many 
homologous (murine EC, EW, EDIM, ETD) and some heterologous (simian RRV) RVs develop 
diarrheal disease, but only during the first two weeks of life. Afterwards, these viruses cause 
asymptomatic infections in the mouse [21]. Early studies showed that treatment of neonatal mice with 
murine type I IFN prior to or after infection with EC RV had no effect on viral replication or diarrhea. 
This established that RVs have mechanisms for overcoming IFN-dependent antiviral responses. 
Further support for this idea came from the observation that diarrhea and virus shedding were not 
significantly reduced in IFN type I or type II receptor knockout (KO) mice [65].  
Infection of the sucking mouse with some homologous RV strains (e.g., EC) leads not only to an 
enteric infection, but also to a systemic infection with the virus replicating in several internal organs. Viruses 2009, 1                                       
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In addressing factors affecting virus spread, Feng et al. [66] found that enteric and systemic replication 
of the EC virus did not differ between wild-type and IFN signaling-deficient mice   
(IFN-// receptor KO or STAT1 KO). However, enteric and systemic replication of a heterologous 
simian strain (RRV) was significantly increased in mice deficient in type I and type II IFN signaling 
(IFN-// receptor KO or STAT1 KO) [66]. In adult mice, STAT1 deficiency was associated with 
increased viral shedding of the heterologous simian strain RRV [98]. These results suggest that IFN 
signaling has a role in modulating RV infection, but that some RV strains can antagonize this effect. 
Additional studies using primary mouse embryonic fibroblasts (MEFs) found that the replication of 
some heterologous RV strains (UK, NCDV, and OSU) was restricted in wild-type MEFs, but not in 
IFN signaling-deficient (IFN-// receptor KO or STAT1 KO) MEFs. However, homologous murine 
strains and the heterologous simian strain RRV replicated to similar titers in wild-type and IFN 
signaling-deficient MEFs. By analyzing a panel of reassortant viruses, the ability of RRV to replicate 
efficiently in wild-type MEFs was mapped to the NSP1 gene. Strains that replicated well were able to 
degrade endogenous IRF3 in wild-type MEFs, thereby inhibiting IFN- secretion [91]. In contrast, 
heterologous strains that replicated poorly in wild-type MEFs failed to degrade IRF3 and stimulated 
the secretion of IFN-. The production of IFN- was dependent on viral replication, which triggered 
phosphorylation of IRF3. Though replication was restricted in wild-type MEFs, these strains grew well 
in IFN signaling-deficient MEFs. Only NSP1 was associated with a differential growth advantage in 
the presence of an intact IFN signaling system [91]. These results suggest strain-specific differences 
exist in NSP1-mediated degradation of IRF3 and suppression of IFN- secretion. Bovine UK RV, one 
of the RV strains with restricted replication in MEFs that was unable to degrade endogenous murine 
IRF3, was also unable to degrade ectopically expressed murine IRF3 in simian Cos7 cells. This was 
not due to an inherent inability to degrade IRF proteins in general, as this strain was able to degrade 
endogenous simian IRF3 and ectopically expressed human IRF3 in MEFs [92]. Studies on the abilities 
of various heterologous and homologous strains of RV to replicate in MEFs continue to provide 
greater understanding into the potential role of NSP1 in RV host range restriction and cell tropism.   
3.4. NSP1 as an E3 Ubiquitin Ligase 
NSP1 has several characteristics that suggest it may function as a viral E3-ubiquitin (Ub) ligase. 
Perhaps central among these is that NSP1 contains a RING domain similar to that of some E3 ligases 
and that the protein induces the proteasomal degradation of target proteins. In addition, NSP1 is itself 
susceptible to proteasomal degradation, and treatment with proteasome inhibitors leads to an increased 
accumulation of NSP1 [80,90,92]. The degradation of NSP1 is likely mediated by polyubiquitination, 
as inhibition of the E1 Ub-activating enzyme activity enhances NSP1 accumulation [92]. 
Ubiquitination places signals on proteins that cause their redistribution in the cell or degradation by 
the proteasome. Polyubiquitination of a protein occurs through a cascade of events, whereby an E1  
Ub-activating enzyme transfers the Ub moiety to an E2 Ub-conjugating enzyme. The E2 then interacts 
with one of two classes of E3 Ub ligases, which differ markedly in the mechanism by which they 
direct the ubiquitination of target proteins. The HECT domain-containing E3 Ub ligases undergo 
transient ubiquitination by E2 ligases, and then transfer the Ub moiety onto the target protein. In Viruses 2009, 1                                       
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contrast, the RING domain-containing E3 ligases act as an adaptor between the target protein and the 
E2 ligase, which directly transfers the Ub moiety onto the target.  
NSP1 contains a conserved cysteine-histidine sequence in its N-terminal region proposed to form 
zinc fingers [75,79]. Subfamilies of zinc finger proteins are generally classified by the order of the 
zinc-coordinating cysteine (C) and histidine (H) residues that serve as metal ligands. The classic RING 
finger domain consists of a signature C3-H-C4 motif, while the classic PHD motif is C4-H-C3 [99]. 
Some viral immunomodulatory proteins, such as Kaposi’s sarcoma herpesvirus K3 and K5, which 
were initially classified as PHD proteins according to their C4-H-C3 motif, have more recently been 
described as variants of the RING domain family, termed viral RING (vRING) [100]. These vRING 
proteins possess ubiquitin ligase activity, whereas classically defined PHD proteins do not. Additional 
criteria used to classify PHD domains include the presence of a tryptophan residue, which is positioned 
two amino acids upstream of metal ligand 7. The vRING domain, however, possesses two invariant 
tryptophan residues, which are located one amino acid downstream of metal ligand 1 and three amino 
acids upstream of metal ligand 6. Group A RV NSP1 proteins possess a C4-H-C3 core motif similar to 
that of PHD and vRING domains (Figure 3B, C). This region of NSP1 includes two highly conserved 
tryptophan residues; yet neither matches the positioning of the conserved PHD-specific tryptophan 
residue. Instead, the NSP1 tryptophan residues are positioned similar to those of vRING proteins. The 
first tryptophan of the NSP1 RING domain is one residue upstream of metal ligand 1 while the second 
is two residues upstream of metal ligand 6. An additional feature of vRING proteins is the predicted 
presence of transmembrane helices that direct these ubiquitin ligases to their targets, membrane-bound 
MCH class I proteins; however, this feature is not shared by NSP1. Based on sequence analysis, NSP1 
shares homology with vRING proteins. Based on functional analysis, NSP1 induces the proteasomal-
dependent degradation of IRF family members. Together, the sequence and function of NSP1 support 
the hypothesis that the protein functions as an E3 ubiquitin ligase. However, direct evidence in support 
of this has yet to be obtained. 
3.5. NSP1 Similarities to Other Viral Proteins 
Viruses use a diverse array of approaches to counteract the host IFN-signaling pathway (see [101] 
and [102] for review). Viruses can disrupt nearly every stage of the IFN response including early 
dsRNA signaling events (e.g., RIG-I, MDA5), the IFN receptor-signaling pathway (e.g., JAK, STAT), 
or specific ISG products (e.g., PKR or MxA). Like RVs, several other viruses suppress type I IFN 
expression by interfering with the IRF3 pathway, though the mechanisms of IRF3 antagonism vary. 
The human papillomavirus 16 protein E6 binds to IRF3 preventing transcription of IFN-. However, 
the binding of E6 to IRF3 does not induce its ubiquitination or proteasomal degradation [103]. 
Classical swine fever virus (CSFV) downregulates the expression of IRF3, and the viral protein N
pro 
mediates this effect [104]. N
pro also associates with IRF3 and induces its degradation in a proteasome-
dependent manner [105]. This is the same mechanism used by the related virus bovine viral diarrhea 
virus (BVDV) [106,107]. However, IRF7 expression does not appear to be affected by N
pro [105]. 
Characterization of N
pro shows that it is a zinc-binding protein, and that the zinc-binding site is 
required for IRF3 degradation and inhibition of IFN- production. N
pro contains a metal binding 
TRASH (trafficking, resistance and sensing of heavy metals) motif at its C terminus, rather than the Viruses 2009, 1                                       
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RING-finger motif typical of E3 ubiquitin ligases [108]. This mechanism of IRF3 inhibition is similar 
to the activity of RV NSP1, though it does not appear to be as broadly active as NSP1. 
4. Conclusions and Perspectives 
Although the NSP1 proteins of different RV strains can vary in their activities, it is clear that NSP1 
is an antagonist of the type I IFN induction pathway. Of the types of NSP1 examined to date, most 
induce the proteasomal degradation of one or more of the IRF proteins (IRF3, IRF5, and IRF7) 
involved in stimulating IFN expression. However, there are exceptions such as OSU NSP1, which 
blocks IFN- induction by inducing the degradation of -TrCP, a protein that is necessary for NF-B 
activation. It is important to note that our current understanding of NSP1 activities is based chiefly on 
the study of relatively few strains of cell culture-adapted animal RVs. Thus, we may have a somewhat 
skewed perspective of what is typical for NSP1. Moreover, it is possible that the design of the assay 
systems used in testing the activities of NSP1 may have introduced biases into experimental results. 
For example, whether an NSP1 protein can degrade an IRF target in an assay system may depend not 
only on the viral source of NSP1, but also on the species origin of the target.  
NSP1 has been established to interact with several host proteins, including those in the IRF family 
and -TrCP. It is quite likely that the function of NSP1 requires it to interact with other host proteins 
as well, mostly notably the E2 ligases. It is possible that failures noted in the ability of some NSP1 
proteins to degrade target proteins may not stem from the inability of NSP1 to physically engage a 
target, but may instead be due to the failure of an E2 ligase to interact successfully with an NSP1-
target protein complex. Certainly, the lack of compatibility between the host E2 ligase and NSP1 could 
be a defining factor in RV host range restriction and cell tropism. Also unresolved is the relative 
importance of the strength and stability of the interaction between NSP1 and its target as a factor in 
target degradation.  
Currently, no single sequence feature of NSP1 has been identified that can be tied to the ability of 
some RV strains but not others to degrade IRF3. Phylogenetic analyses rules out any obvious link 
between the activities of NSP1 and genotype of the protein, or the serotype or host range of the virus 
encoding the protein. Studies of the NSP1 activities of a diverse collection of RV isolates have been 
slowed by difficulties raising hyperimmune serum against NSP1, reflecting the low antigenicity of the 
protein [81]. Additionally, the few antibodies that have been generated to recognize NSP1 are 
exquisitely specific, with little to no capacity to cross-react with NSP1s from different RV species. The 
development of antibodies to several strains of RV NSP1 or a single highly cross-reactive antibody 
would greatly enhance future studies of the protein and its activities. 
An important unresolved question is whether the RNA-binding activity of NSP1 has a role in 
suppressing IFN induction. One possibility is that NSP1 may use this activity to sequester viral RNAs 
in infected cells, similar to the IFN-antagonist protein of influenza A virus NS1, thereby preventing 
interactions with PRRs [109-111]. Some evidence indicates that RV infection might stimulate innate 
immune responses through recognition of viral RNAs by RIG-I [112]. However, the association of 
NSP1 with PRRs upstream of IRF3 remains unexplored. 
NSP1 plays a role in RV pathogenesis as a broad-spectrum antagonist of IFN induction, yet many 
unanswered questions remain. Are there other cellular targets degraded or otherwise targeted for Viruses 2009, 1                                       
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inactivation by NSP1? Does the RNA-binding activity of NSP1 play a role in subverting the IFN 
response? What are the sequence determinants of different NSP1 activities? Is NSP1 an E3 ubiquitin 
ligase, and if so, what is its E2 partner? Does NSP1 from human strains of RV share the activities that 
have been described for the cell culture-adapted animal strains? The answers to such questions will 
lend insight into how NSP1 enhances virulence of RV in infected hosts. There are several challenges to 
studying RV NSP1, including difficulties in adapting and growing human RVs in cell culture, the 
expense and relative lack of large animal models, and the absence of an appropriate reverse genetics 
system. However, developing solutions to these challenges will enhance and renew efforts to create 
new and more effective vaccine candidates. 
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